Henri S. Lichenstein

7.7k total citations · 3 hit papers
59 papers, 6.3k citations indexed

About

Henri S. Lichenstein is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Henri S. Lichenstein has authored 59 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 18 papers in Immunology and 12 papers in Oncology. Recurrent topics in Henri S. Lichenstein's work include Immune Response and Inflammation (15 papers), Histone Deacetylase Inhibitors Research (9 papers) and Protein Degradation and Inhibitors (8 papers). Henri S. Lichenstein is often cited by papers focused on Immune Response and Inflammation (15 papers), Histone Deacetylase Inhibitors Research (9 papers) and Protein Degradation and Inhibitors (8 papers). Henri S. Lichenstein collaborates with scholars based in United States, United Kingdom and Denmark. Henri S. Lichenstein's co-authors include Samuel D. Wright, Mark M. Wurfel, Eric Hailman, Michael Jeffers, Mark M. Zukowski, Leigh Busse, Michael J. Kelley, Rodger P. McEver, Richard D. Cummings and Kevin L. Moore and has published in prestigious journals such as Cell, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Henri S. Lichenstein

59 papers receiving 6.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

1994 632 citations Eric Hailman, Henri S. Lichenstein et al. The Journal of Experimental Medicine profile →
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

2007 599 citations Michael Jeffers, Xiaozhong Qian et al. profile →
P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin.

1995 587 citations Kevin L. Moore, Kamala D. Patel et al. The Journal of Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henri S. Lichenstein United States	40	3.3k	2.1k	998	839	707	59	6.3k
K. Mark Coggeshall United States	49	3.6k 1.1×	3.9k 1.8×	919 0.9×	710 0.8×	407 0.6×	110	7.3k
Mark Labow United States	37	3.3k 1.0×	1.7k 0.8×	736 0.7×	609 0.7×	555 0.8×	59	6.1k
Stephen M. Robbins Canada	44	2.9k 0.9×	2.3k 1.1×	760 0.8×	477 0.6×	458 0.6×	90	6.1k
Michael R. Gold Canada	49	3.1k 1.0×	4.1k 1.9×	925 0.9×	710 0.8×	643 0.9×	136	7.9k
Isabelle Maridonneau‐Parini France	49	2.4k 0.7×	2.3k 1.1×	786 0.8×	664 0.8×	452 0.6×	123	6.6k
Glenn C. Rice United States	27	2.3k 0.7×	2.2k 1.0×	1.4k 1.4×	516 0.6×	705 1.0×	55	5.5k
Cosima T. Baldari Italy	47	3.6k 1.1×	3.4k 1.6×	972 1.0×	279 0.3×	451 0.6×	228	7.8k
Anthony DeFranco United States	59	3.1k 0.9×	6.2k 2.9×	957 1.0×	707 0.8×	836 1.2×	116	9.2k
Philip E. Auron United States	45	4.2k 1.3×	3.9k 1.8×	1.4k 1.4×	342 0.4×	1.1k 1.6×	96	8.5k
Václav Hořejšı́ Czechia	51	4.1k 1.2×	4.6k 2.1×	795 0.8×	894 1.1×	410 0.6×	168	8.4k

Countries citing papers authored by Henri S. Lichenstein

Since Specialization

Citations

This map shows the geographic impact of Henri S. Lichenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henri S. Lichenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henri S. Lichenstein more than expected).

Fields of papers citing papers by Henri S. Lichenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henri S. Lichenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henri S. Lichenstein. The network helps show where Henri S. Lichenstein may publish in the future.

Co-authorship network of co-authors of Henri S. Lichenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Henri S. Lichenstein. A scholar is included among the top collaborators of Henri S. Lichenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henri S. Lichenstein. Henri S. Lichenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dizon, Don S., Lars Damstrup, Neil J. Finkler, et al.. (2012). Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. International Journal of Gynecological Cancer. 22(6). 979–986. 66 indexed citations

Grauslund, Morten, Thomas Litman, Laura S. Collins, et al.. (2008). Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Molecular Cancer. 7(1). 70–70. 35 indexed citations

Qian, Xiaozhong, et al.. (2007). Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. International Journal of Cancer. 122(6). 1400–1410. 79 indexed citations

Warren, Katherine E., et al.. (2007). Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemotherapy and Pharmacology. 62(3). 433–437. 23 indexed citations

Qian, Xiaozhong, William J. LaRochelle, Gulshan Ara, et al.. (2006). Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Molecular Cancer Therapeutics. 5(8). 2086–2095. 117 indexed citations

Dhanabal, Mohanraj, Michael Jeffers, William J. LaRochelle, & Henri S. Lichenstein. (2005). Angioarrestin: A unique angiopoietin-related protein with anti-angiogenic properties. Biochemical and Biophysical Research Communications. 333(2). 308–315. 20 indexed citations

Álvarez, Enrique, Edward G. Fey, Pascal Valax, et al.. (2003). Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.. PubMed. 9(9). 3454–61. 45 indexed citations

Jeffers, Michael, William J. LaRochelle, & Henri S. Lichenstein. (2002). Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opinion on Therapeutic Targets. 6(4). 469–482. 46 indexed citations

Zhang, Hongwei, Henri S. Lichenstein, Nilofer Qureshi, et al.. (2000). Neutrophil Activation by Bacterial Lipoprotein Versus Lipopolysaccharide: Differential Requirements for Serum and CD14. The Journal of Immunology. 164(5). 2674–2683. 68 indexed citations

10.

Yang, Zhengang, Henri S. Lichenstein, & Philip N. Bochsler. (1997). Effects of recombinant soluble CD14 on association of bacterial lipopolysaccharide with bovine alveolar macrophages in vitro. Journal of Endotoxin Research. 4(3). 205–213. 1 indexed citations

11.

Ryan, Liv, et al.. (1997). Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor. Infection and Immunity. 65(1). 89–94. 41 indexed citations

12.

Jarvis, Bruce W., Henri S. Lichenstein, & N Qureshi. (1997). Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS. Infection and Immunity. 65(8). 3011–3016. 32 indexed citations

13.

Diener, Katrina, et al.. (1996). Molecular Cloning and Characterization of a Novel Protein Kinase with a Catalytic Domain Homologous to Mitogen-activated Protein Kinase Kinase Kinase. Journal of Biological Chemistry. 271(49). 31607–31611. 131 indexed citations

14.

McGinley, Michael D., Linda O. Narhi, Michael J. Kelley, et al.. (1995). CD14: Physical Properties and Identification of an Exposed Site That Is Protected by Lipopolysaccharide. Journal of Biological Chemistry. 270(10). 5213–5218. 53 indexed citations

15.

Moore, Kevin L., Kamala D. Patel, Richard E. Bruehl, et al.. (1995). P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin.. The Journal of Cell Biology. 128(4). 661–671. 587 indexed citations breakdown →

16.

Juan, Todd, Eric Hailman, Michael J. Kelley, Samuel D. Wright, & Henri S. Lichenstein. (1995). Identification of a Domain in Soluble CD14 Essential for Lipopolysaccharide (LPS) Signaling but Not LPS Binding. Journal of Biological Chemistry. 270(29). 17237–17242. 57 indexed citations

17.

Kusunoki, Takashi, Eric Hailman, Todd Juan, Henri S. Lichenstein, & Samuel D. Wright. (1995). Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses.. The Journal of Experimental Medicine. 182(6). 1673–1682. 149 indexed citations

18.

Juan, Todd, Michael J. Kelley, David A. Johnson, et al.. (1995). Soluble CD14 Truncated at Amino Acid 152 Binds Lipopolysaccharide (LPS) and Enables Cellular Response to LPS. Journal of Biological Chemistry. 270(3). 1382–1387. 69 indexed citations

19.

Juan, Todd, Eric Hailman, Michael J. Kelley, et al.. (1995). Identification of a Lipopolysaccharide Binding Domain in CD14 between Amino Acids 57 and 64. Journal of Biological Chemistry. 270(10). 5219–5224. 102 indexed citations

20.

Hailman, Eric, Henri S. Lichenstein, Mark M. Wurfel, et al.. (1994). Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.. The Journal of Experimental Medicine. 179(1). 269–277. 632 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact